3-Hydrazino-6,7-dihydro-5h-benzo[6,7]cyclohepta[1,2-c]pyridazine → (R)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-C]pyridazin-3-YL)-N3-(7-(pyrrolidin-1-YL)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-YL)-1H-1,2,4-triazole-3,5-diamine

HRID 1749340Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1749340
[C:1]([N:3]=[C:4](OC1C=CC=CC=1)[NH:5][C:6]1[CH:7]=[CH:8][C:9]2[CH2:15][CH2:14][C@H:13]([N:16]3[CH2:20][CH2:19][CH2:18][CH2:17]3)[CH2:12][CH2:11][C:10]=2[CH:21]=1)#[N:2].[C:29]([N:31]=[C:32](OC1C=CC=CC=1)[NH:33][C:34]1[CH:35]=[CH:36][C:37]2[CH2:43][CH2:42][C@@H:41]([N:44]3[CH2:48][CH2:47][CH2:46][CH2:45]3)[CH2:40][CH2:39][C:38]=2[CH:49]=1)#[N:30].[NH:57]([C:59]1[N:64]=[N:63][C:62]2[C:65]3[CH:73]=[CH:72][CH:71]=[CH:70][C:66]=3[CH2:67][CH2:68][CH2:69][C:61]=2[CH:60]=1)[NH2:58]>>[N:63]1[C:62]2[C:65]3[CH:73]=[CH:72][CH:71]=[CH:70][C:66]=3[CH2:67][CH2:68][CH2:69][C:61]=2[CH:60]=[C:59]([N:57]2[C:1]([NH2:2])=[N:3][C:4]([NH:5][C:6]3[CH:7]=[CH:8][C:9]4[CH2:15][CH2:14][C@H:13]([N:16]5[CH2:17][CH2:18][CH2:19][CH2:20]5)[CH2:12][CH2:11][C:10]=4[CH:21]=3)=[N:58]2)[N:64]=1.[N:63]1[C:62]2[C:65]3[CH:73]=[CH:72][CH:71]=[CH:70][C:66]=3[CH2:67][CH2:68][CH2:69][C:61]=2[CH:60]=[C:59]([N:57]2[C:29]([NH2:30])=[N:31][C:32]([NH:33][C:34]3[CH:35]=[CH:36][C:37]4[CH2:43][CH2:42][C@@H:41]([N:44]5[CH2:45][CH2:46][CH2:47][CH2:48]5)[CH2:40][CH2:39][C:38]=4[CH:49]=3)=[N:58]2)[N:64]=1

Komponenten

5

Edukt 3

HCID 592955463-Hydrazino-6,7-dihydro-5h-benzo[6,7]cyclohepta[1,2-c]pyridazineHCID 178512232HCID 178512232, VerbindungHCID 178512233HCID 178512233, Verbindung

Produkt 2

HCID 25126770(R)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-C]pyridazin-3-YL)-N3-(7-(pyrrolidin-1-YL)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-YL)-1H-1,2,4-triazole-3,5-diamineHCID 46215462Bemcentinib

Versuchsvorschrift

Phenyl (S)-N′-cyano-N-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)carbamimidate and phenyl (R)-N′-cyano-N-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)carbamimidate were treated with 3-hydrazino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazine in a similar manner as described above in Synthetic Example 2 to yield 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine and 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(R)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine. For example, a suspension of a single enantiomer of phenyl N′-cyano-N-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)carbamimidate (0.06 g, 0.16 mmol) and 3-hydrazino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazine (0.036 g, 0.16 mmol) in 1 mL of IPA was stirred at 90° C. for 18 h. After cooling to ambient temperature, the solvent was evaporated and the residue was purified by HPLC to provide enantiomerically pure 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(R)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine as a yellow solid (0.04 g, 50%). 1H NMR (DMSO-d6, 300 MHz) 9.11 (s, 1H), 7.94 (s, 1H), 7.85 (br s, 2H), 7.72 (m, 1H), 7.46 (m, 3H), 7.37 (m, 2H), 7.06 (m, 1H), 3.46 (m, 4H), 3.12 (m, 2H), 2.72 (m, 4H), 2.61 (m, 3H), 2.25 (m, 5H), 2.09-1.82 (m, 5H) ppm; MS (ES) 507 (M+H).

Quellen und Nachweise

ORD-Eintrag
ord-09edf794ac38409a807f00c8d2f488ce
Quelldatensatz
uspto-grants-2015_10
Patentnummer
US09156820B2

Notizen zur Reaktion

Wird geladen…